# CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma

> **NCT01673672** · PHASE2 · TERMINATED · sponsor: **Cytos Biotechnology AG** · enrollment: 365 (actual)

## Conditions studied

- Moderate to Severe Allergic Asthma

## Interventions

- **BIOLOGICAL:** CYT003
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT01673672
- **Lead sponsor:** Cytos Biotechnology AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-11
- **Primary completion:** 2014-05
- **Final completion:** 2014-05
- **Target enrollment:** 365 (ACTUAL)
- **Why stopped:** primary endpoint missed
- **Last updated:** 2014-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01673672

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01673672, "CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01673672. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*